Nalu-0018

Nalu-0018 is a preclinical-stage therapeutic candidate being developed by Nalu Bio, a biotechnology company focused on the chemical synthesis of cannabinoids. Nalu-0018 is part of a pipeline of chemically synthesized, bio-identical cannabinoids and cannabinoid derivatives produced through a proprietary chemistry-based platform. This approach aims to provide high-purity compounds that are consistent and free from the variability and impurities (such as THC or heavy metals) often found in plant-derived extracts. The program is currently targeting metabolic and immune-related diseases, leveraging the therapeutic potential of the cannabinoid scaffold to modulate relevant biological pathways.